Success Metrics

Clinical Success Rate
68.8%

Based on 11 completed trials

Completion Rate
69%(11/16)
Active Trials
0(0%)
Results Posted
18%(2 trials)
Terminated
5(31%)

Phase Distribution

Ph phase_3
1
6%
Ph phase_1
8
50%
Ph phase_2
7
44%

Phase Distribution

8

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
8(50.0%)
Phase 2Efficacy & side effects
7(43.8%)
Phase 3Large-scale testing
1(6.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

68.8%

11 of 16 finished

Non-Completion Rate

31.3%

5 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(11)
Terminated(5)

Detailed Status

Completed11
Terminated5

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
68.8%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (50.0%)
Phase 27 (43.8%)
Phase 31 (6.3%)

Trials by Status

completed1169%
terminated531%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_2

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NCT00427349
terminatedphase_2

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

NCT00369070
completedphase_1

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

NCT00861419
terminatedphase_2

An Open Label Treatment Extension Study of AMG 706

NCT00360867
terminatedphase_2

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

NCT00356681
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00427349Phase 2

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Completed
NCT00369070Phase 2

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Terminated
NCT00861419Phase 1

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Completed
NCT00360867Phase 2

An Open Label Treatment Extension Study of AMG 706

Terminated
NCT00356681Phase 2

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Terminated
NCT00460317Phase 3

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Terminated
NCT00101907Phase 1

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Terminated
NCT00254267Phase 2

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

Completed
NCT00121628Phase 2

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Completed
NCT00322400Phase 1

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Completed
NCT00093873Phase 1

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Completed
NCT00089960Phase 2

Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

Completed
NCT00101894Phase 1

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Completed
NCT01386866Phase 1

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Completed
NCT00448786Phase 1

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

Completed
NCT01235416Phase 1

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16